IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Laurel Wealth Advisors LLC

Laurel Wealth Advisors LLC reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 4,562 shares of the medical research company’s stock after selling 148 shares during the period. Laurel Wealth Advisors LLC’s holdings in IQVIA were worth $1,056,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Jag Capital Management LLC lifted its stake in IQVIA by 0.4% in the 4th quarter. Jag Capital Management LLC now owns 11,401 shares of the medical research company’s stock worth $2,638,000 after purchasing an additional 49 shares in the last quarter. Parkside Financial Bank & Trust lifted its stake in IQVIA by 18.1% in the 3rd quarter. Parkside Financial Bank & Trust now owns 346 shares of the medical research company’s stock worth $68,000 after purchasing an additional 53 shares in the last quarter. Private Advisor Group LLC lifted its stake in IQVIA by 1.2% in the 3rd quarter. Private Advisor Group LLC now owns 4,818 shares of the medical research company’s stock worth $948,000 after purchasing an additional 56 shares in the last quarter. B. Riley Wealth Advisors Inc. raised its position in shares of IQVIA by 1.6% during the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 3,568 shares of the medical research company’s stock valued at $702,000 after buying an additional 56 shares during the period. Finally, Greenleaf Trust raised its position in shares of IQVIA by 1.9% during the 4th quarter. Greenleaf Trust now owns 3,154 shares of the medical research company’s stock valued at $730,000 after buying an additional 58 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently commented on IQV shares. Truist Financial lifted their price target on shares of IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Robert W. Baird lifted their price target on shares of IQVIA from $226.00 to $251.00 and gave the company a “neutral” rating in a research report on Thursday, February 15th. Leerink Partnrs reaffirmed an “outperform” rating on shares of IQVIA in a research report on Monday, February 26th. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Finally, Guggenheim downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Three investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $256.80.

Insider Activity

In other news, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares of the company’s stock, valued at $5,031,894. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the transaction, the insider now directly owns 796,752 shares in the company, valued at $199,610,278.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the transaction, the insider now owns 20,836 shares in the company, valued at $5,031,894. The disclosure for this sale can be found here. Over the last three months, insiders sold 41,285 shares of company stock valued at $10,331,003. Insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

IQV traded up $0.90 on Friday, reaching $234.88. The company had a trading volume of 697,640 shares, compared to its average volume of 761,918. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The stock has a market capitalization of $42.63 billion, a PE ratio of 32.22, a P/E/G ratio of 2.26 and a beta of 1.50. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12. The stock has a 50-day moving average price of $245.28 and a 200-day moving average price of $223.02.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating analysts’ consensus estimates of $2.82 by $0.02. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The firm had revenue of $3.87 billion during the quarter, compared to analysts’ expectations of $3.80 billion. During the same period in the previous year, the company earned $2.54 earnings per share. IQVIA’s quarterly revenue was up 3.5% compared to the same quarter last year. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.12 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.